Mineralys Therapeutics Files 8-K
Ticker: MLYS · Form: 8-K · Filed: Jun 17, 2025 · CIK: 1933414
Sentiment: neutral
Topics: sec-filing, 8-k, reporting
TL;DR
Mineralys filed an 8-K, standard procedure, no major news yet.
AI Summary
Mineralys Therapeutics, Inc. filed an 8-K on June 17, 2025, reporting on several items including Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The filing does not contain specific financial figures or material event details within the provided text, but indicates standard reporting procedures.
Why It Matters
This filing indicates Mineralys Therapeutics is adhering to its reporting obligations with the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not disclose any new material risks or events.
Key Players & Entities
- Mineralys Therapeutics, Inc. (company) — Registrant
- June 17, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- 150 N. Radnor Chester Road, Suite F200, Radnor, Pennsylvania 19087 (address) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Mineralys Therapeutics, Inc.?
The filing serves to report on Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits, as of June 17, 2025.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is June 17, 2025.
In which state is Mineralys Therapeutics, Inc. incorporated?
Mineralys Therapeutics, Inc. is incorporated in Delaware.
What is the business address of Mineralys Therapeutics, Inc.?
The business address is 150 N. Radnor Chester Road, Suite F200, Radnor, Pennsylvania 19087.
What is the telephone number listed for Mineralys Therapeutics, Inc.?
The telephone number is (888) 378-6240.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 17, 2025 regarding Mineralys Therapeutics, Inc. (MLYS).